CME Journal Supplement

Frequently Asked Questions in the Evaluation and Management of Overactive Bladder
If overactive bladder (OAB) is so prevalent, why don’t I see more adults with OAB symptoms in my practice? Why do some patients with OAB have urgency incontinence while others remain dry? Do other conditions mimic or cause OAB symptoms? How do I choose among the available OAB medications? Is medical therapy the only treatment option? Why is treatment adherence such a problem? What if my patient fails initial therapy? At what point should I send my patient to a urologist?

Find the answers to these and other important questions about managing patients with OAB in this expert-authored, peer-reviewed supplement to The Journal of Family Practice.

Educational Objectives

Step 1
Step 2
Step 3
Educational Objectives
At the conclusion of this activity, participants should be able to:
  • Review the prevalence and pathophysiology of overactive bladder (OAB) and barriers that may exist to the diagnosis and evaluation of patients with OAB
  • Discuss the role of behavioral therapy in the management of OAB and optimizing outcomes in the management of OAB
  • Recognize when referral to a urologist is appropriate and the options that a urologist may present to patients for refractory OAB

Faculty
Pamela I. Ellsworth, MD, Program Chair
Associate Professor of Surgery
Division of Urology
The Warren Alpert Medical School of Brown University
Providence, RI

Stephen A. Brunton, MD, Program Co-Chair
Adjunct Clinical Professor
Department of Family Medicine
University of North Carolina at Chapel Hill
Chapel Hill, NC
Director of Faculty Development
Cabarrus Family Residency Program
Concord, NC

Alan J. Wein, MD, PhD (Hon), Program Co-Chair
Professor and Chair
Department of Surgery
Division of Urology
University of Pennsylvania School of Medicine
Chief, Division of Urology
University of Pennsylvania Health System
Philadelphia, PA

Eric S. Rovner, MD
Professor of Urology
Director, Section of Female Urology, Neurourology and Urodynamics
Department of Urology
Medical University of South Carolina
Charleston, SC


Faculty Disclosures
In accordance with the disclosure policy of the Warren Alpert Medical School of Brown University as well as standards set forth by the Accreditation Council for Continuing Medical Education, all speakers and individuals in a position to control the content of a CME activity are required to disclose relevant financial relationships with commercial interests (within the past 12 months). Disclosures of this activity’s speakers and planning committee have been reviewed and all identified conflicts of interest, if applicable, have been resolved.

Pamela Ellsworth, MD, is a consultant for Pfizer Inc and Allergan, Inc.; she is a speaker for Pfizer Inc; she has participated in speaker training for Novartis Pharmaceuticals Corporation; and she has participated in clinical research studies sponsored by Novartis Pharmaceuticals Corporation and Pfizer Inc. Stephen A. Brunton, MD, has no financial interests to disclose. Alan J. Wein, MD, PhD (Hon), is a consultant for Pfizer Inc, Astellas Pharma US, Inc., and Novartis Pharmaceuticals Corporation. Eric Rovner, MD, is a consultant for Allergan, Inc., Pfizer Inc, Astellas Pharma US, Inc., Solace Therapeutics, and Tengion; he is a speaker for Allergan, Inc., Pfizer Inc, and Astellas Pharma US, Inc.; and he has received grant or research support from Allergan, Inc., Pfizer Inc, Contura International A/S, and Solace Therapeutics.
Step 2 - Journal Supplement  /  CME Information